Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Follow-Up Questions
Who is the CEO of Foghorn Therapeutics Inc?
Mr. Adrian Gottschalk is the President of Foghorn Therapeutics Inc, joining the firm since 2017.
What is the price performance of FHTX stock?
The current price of FHTX is $3.51, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Foghorn Therapeutics Inc?
Foghorn Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Foghorn Therapeutics Inc market cap?
Foghorn Therapeutics Inc's current market cap is $198.4M
Is Foghorn Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Foghorn Therapeutics Inc, including 4 strong buy, 8 buy, 1 hold, 0 sell, and 4 strong sell
